Initial focus is on treatments for metabolic diseases and CNS disorders.



Ambrx signed a research collaboration with Eli Lilly to discover and develop novel treatments in several therapeutic areas including metabolic diseases, central nervous system disorders, and other diseases.


The companies will apply Ambrx’ protein optimization technology, ReCODE™, with Lilly’s expertise in biologics discovery, development, and commercialization to pursue drug candidates including therapeutic antibodies and improved variants of native proteins.


Under the terms of the agreement, Ambrx will receive an initial upfront payment and ongoing research support payments. Additionally, Ambrx may receive potential research and development milestones and additional royalties if assets resulting from the collaboration are successfully commercialized.








This site uses Akismet to reduce spam. Learn how your comment data is processed.